PharmaCyte Biotech, Inc. (PMCB): auditor change — Auditor Armanino LLP resigns due to exit from public audits; no disagreements

PharmaCyte Biotech, Inc.

Armanino resigned effective upon new auditor appointment or filing of Q for Jan 31, 2024.
Resignation solely due to Armanino's exit from public company audit services, not company-related.
No disagreements on accounting principles or reportable events in FY 2022 and FY 2023.
Company began process to engage a new independent auditor for FY ending April 30, 2024.
Armanino's audit reports for recent fiscal years were unqualified.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Armanino LLP resigned as auditor of PharmaCyte Biotech, Inc..

Action: resignation
Auditor: Armanino LLP

Exact text from the filing

On August 1, 2023, PharmaCyte Biotech, Inc. (the “Company”) was informed by Armanino LLP (“Armanino”), the Company’s current independent registered public accounting firm, that Armanino will resign as the Company’s independent auditor (see below explanation for resignation which is not related to any actions taken by the Company) effective as of the earlier of (a) the date the Company engages a new independent registered public accounting firm or (b) the filing of the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended January 31, 2024.

View on SEC.gov

8 auditor changes filed in the last 30 days. Browse all auditor changes →

PharmaCyte Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-23-005293

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.